PDF(Pubmed)
Abstract：
UNASSIGNED: To optimise the dosing regimen of meropenem for treating Pseudomonas aeruginosa (PA) infections in critically ill patients with augmented renal clearance (ARC) using pharmacokinetic/pharmacodynamic (PK/PD) principles and Monte Carlo simulation (MCS).
UNASSIGNED: This research involves an MCS based on PK data from patients with ARC and a minimum inhibitory concentration (MIC) distribution of PA. This study simplifies the methods section, focusing on the critical aspects of simulation and target values for effective treatment.
UNASSIGNED: The study highlights key findings and emphasises that tailored dosing based on bacterial MIC values is essential for patients with ARC. It also notes that empirical treatment in patients with ARC should consider the MIC distribution, with 2 g every (q) 6 h administered to achieve the PK/PD target, while 3 g q 6 h is effective in inhibiting resistance.
UNASSIGNED: Tailored dosing based on bacterial MIC values is crucial for patients with ARC. Prolonged infusion time alone does not enhance efficacy. Empirical treatment in patients with ARC should consider MIC distribution; a dosage of 2 g q 6 h achieves the PK/PD target, while 3 g q 6 h (≥12 g daily) inhibits resistance.
UNASSIGNED: This research involves an MCS based on PK data from patients with ARC and a minimum inhibitory concentration (MIC) distribution of PA. This study simplifies the methods section, focusing on the critical aspects of simulation and target values for effective treatment.
UNASSIGNED: The study highlights key findings and emphasises that tailored dosing based on bacterial MIC values is essential for patients with ARC. It also notes that empirical treatment in patients with ARC should consider the MIC distribution, with 2 g every (q) 6 h administered to achieve the PK/PD target, while 3 g q 6 h is effective in inhibiting resistance.
UNASSIGNED: Tailored dosing based on bacterial MIC values is crucial for patients with ARC. Prolonged infusion time alone does not enhance efficacy. Empirical treatment in patients with ARC should consider MIC distribution; a dosage of 2 g q 6 h achieves the PK/PD target, while 3 g q 6 h (≥12 g daily) inhibits resistance.
摘要：
■使用药代动力学/药效学（PK/PD）原理和蒙特卡罗模拟（MCS）优化美罗培南的给药方案，用于治疗肾脏清除率（ARC）增强的危重患者的铜绿假单胞菌（PA）感染。
■这项研究涉及基于来自ARC患者的PK数据的MCS和PA的最小抑制浓度（MIC）分布。这项研究简化了方法部分，专注于模拟的关键方面和有效治疗的目标值。
该研究突出了关键发现，并强调基于细菌MIC值的定制剂量对ARC患者至关重要。它还指出，ARC患者的经验治疗应考虑MIC分布，每6小时给药2克，以实现PK/PD目标，而3gq6h对抑制抗性有效。
■根据细菌MIC值定制剂量对ARC患者至关重要。单独延长输注时间并不能提高疗效。ARC患者的经验治疗应考虑MIC分布;2gq6h的剂量达到PK/PD目标，而3gq6h（每天≥12g）抑制抗性。
■这项研究涉及基于来自ARC患者的PK数据的MCS和PA的最小抑制浓度（MIC）分布。这项研究简化了方法部分，专注于模拟的关键方面和有效治疗的目标值。
该研究突出了关键发现，并强调基于细菌MIC值的定制剂量对ARC患者至关重要。它还指出，ARC患者的经验治疗应考虑MIC分布，每6小时给药2克，以实现PK/PD目标，而3gq6h对抑制抗性有效。
■根据细菌MIC值定制剂量对ARC患者至关重要。单独延长输注时间并不能提高疗效。ARC患者的经验治疗应考虑MIC分布;2gq6h的剂量达到PK/PD目标，而3gq6h（每天≥12g）抑制抗性。
